31 Mar 2022
Assets17.74
Total Income22.58
Profit After Tax0.08
NET Worth3.08
Total Borrowing7.61
At a glance
Updated 2026-09-12Accretion Pharmaceuticals is a SME IPO with an issue size of ₹29.75 crore, proposed for listing on NSE SME. The offer opens on 14th May 2025 and closes on 16th May 2025. The issue structure includes a fresh issue of ₹28.26 crore.
Issue details
Listing atNSE SME
Issue typeBook Build Issue
Issue size₹29.75 Cr
Fresh issue₹28.26 Cr
Face value₹10
Price band₹96.00–₹101.00
Allotment19th May 2025
Listing21st May 2025
Grey market
GMP page ↗Latest GMP₹0.00
GMP / upper price0.00%
Est. listing₹101.00
GMP is unofficial sentiment data, not an exchange price.
Timeline
Opens14th May 2025
Closes16th May 2025
Allotment19th May 2025
Refund20th May 2025
Demat20th May 2025
Listing21st May 2025
Subscription demand
Full bidding ↗Total7.67×
Lot size
| Investor | Lots | Shares | Amount |
|---|---|---|---|
| Minimum Bid | 1 | 1200 | ₹121,200 |
Company
Incorporated2012
Use of proceeds
| Object | Amount |
|---|---|
| Capital expenditure towards purchase of new equipment/ machineries, etc. | ₹2.70 Cr |
| Capital expenditure towards upgradation of existing manufacturing facility | ₹4.66 Cr |
| Repayment/prepayme nt of certain borrowings availed by the Company | ₹0.99 Cr |
| Funding working capital requirements of the Company | ₹14.68 Cr |
| General Corporate Purposes | ₹4.43 Cr |
| Issue Expenses | ₹2.30 Cr |
| Total | ₹29.75 Cr |
Financial performance
Year-wise operating scale, profitability and balance-sheet context.Revenue35.75₹ Cr · +5.3% vs prior year
PAT5.24₹ Cr · +35.1% vs prior year
Assets39.99₹ Cr · +47.8% vs prior year
Net Worth13.58₹ Cr · +153.8% vs prior year
Borrowing13.79₹ Cr · +2.3% vs prior year
3-year financial trendRevenue / EBITDA / PAT
₹ crore31 Mar 2023
Assets20.58
Total Income29.53
Profit After Tax0.10
NET Worth3.84
Total Borrowing8.47
31 Mar 2024
Assets27.05
Total Income33.94
Profit After Tax3.88
NET Worth5.35
Reserves and Surplus1.35
Total Borrowing13.48
31 Dec 2024
Assets39.99
Total Income35.75
Profit After Tax5.24
NET Worth13.58
Reserves and Surplus5.41
Total Borrowing13.79
KPIs
| KPI | Mar 31, 2024 |
|---|---|
| ROE | 72.47% |
| ROCE | 36.73% |
| Debt / Equity | 2.52% |
| RoNW | 72.47% |
| PAT Margin | 11.51% |
| Price to Book Value | 7.55 |
Valuation & shareholding
Pre-IPO EPS4.74
Post-IPO EPS6.28
Pre-IPO P/E21.29
Post-IPO P/E16.08
Promoter holding pre100%
Promoter holding post73.48%
Market cap₹112.27 Cr.
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Accretion Pharmaceuticals IPO | — | 35.82 x | — | — |
| Bio Medica IPO | — | 13.45 x | — | — |
| Goldline Pharmaceutical IPO | — | 14.56 x | — | — |
| Speciality Medicines IPO | — | 10.49 x | — | — |
Issue expenses
| Expense | Amount |
|---|---|
| Capital expenditure towards purchase of new equipment/ machineries, etc. | ₹2.70 Cr |
| Capital expenditure towards upgradation of existing manufacturing facility | ₹4.66 Cr |
| Repayment/prepayme nt of certain borrowings availed by the Company | ₹0.99 Cr |
| Funding working capital requirements of the Company | ₹14.68 Cr |
| General Corporate Purposes | ₹4.43 Cr |
| Issue Expenses | ₹2.30 Cr |
| Total | ₹29.75 Cr |
Registrar & lead managers
Registrar
Kfin Technologies Ltd.Lead managers
- Jawa Capital Services Pvt.Ltd.
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-09-12.
IPO UPDATE ALERTS
Register for IPO Updates →Track Accretion Pharmaceuticals without missing an update
Register for subscription, GMP, allotment and listing notifications.